Abstract
With a median age of 70 years at diagnosis, lung cancer is a disease of older persons. As a consequence oncologists are confronted with an increasing older lung cancer population for which treatment decisions are needed. In the past years, the therapeutic landscape of advanced non-small cell lung cancer (NSCLC) has changed impressively with the introduction of targeted therapies and immunotherapy next to chemotherapy. Treatment choices for advanced NSCLC are mainly guided by different tumor-related characteristics. However, in older patients treatment decisions are more complex because of the scarcity of data from large randomized studies in older patients and the heterogeneity of this population with regards to different geriatric domains such as functional status, comorbidity and polypharmacy. The present manuscript reviews available data for the different treatment options for older patients with NSCLC as well as the use of geriatric assessment as an evaluation and guidance tool.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
